Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Biohit OyjLTS:0DRP -3.19%78 Forward PE Ratio is 18.20 as of Jul. 26, 2026. GuruFocus rates LTS:0DRP with a GF Score™ of 78/100 and a GF Value™ of €2.71 (Fairly Valued). The stock has 4 warning signs investors should review. Among 391 Medical Devices & Instruments companies, Biohit Oyj ranks better than 54.99% on this metric.
Biohit Oyj (LTS:0DRP) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Biohit Oyj Forward PE Ratio Related Terms
Biohit Oyj Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for Biohit Oyj's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biohit Oyj Forward PE Ratio Chart
Biohit Oyj Annual Data
Trend
2024-12
2025-12
Forward PE Ratio
14.63
22.31
Biohit Oyj Semi-Annual Data
2024-12
2025-06
2025-12
Forward PE Ratio
14.63
18.60
22.31
LTS:0DRP vs ABT, SYK, MDT: Forward PE Ratio Comparison
For the Medical Devices subindustry, Biohit Oyj's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biohit Oyj Forward PE Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Biohit Oyj's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Biohit Oyj's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Biohit Oyj (LTS:0DRP) has a Forward PE Ratio of 18.20 as of Jul. 26, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Biohit Oyj and its competitors. According to the industry distribution chart, Biohit Oyj ranks #176 out of 391 companies in the Medical Devices & Instruments industry, placing it in the top 45%.
Is Biohit Oyj's Forward PE Ratio too high?
Biohit Oyj's current Forward PE Ratio is 18.20. The Medical Devices & Instruments industry median Forward PE Ratio is 18.69. Biohit Oyj's value of 18.20 is 2.6% below this industry median. Based on the distribution chart, Biohit Oyj ranks #176 out of 391 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Biohit Oyj has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Biohit Oyj's Forward PE Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Biohit Oyj ranks #176 out of 391 companies for Forward PE Ratio. This puts Biohit Oyj in the upper half of its industry. The industry median Forward PE Ratio is 18.69. Biohit Oyj's value of 18.20 is 2.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Medical Devices & Instruments company?
The median Forward PE Ratio among Medical Devices & Instruments companies is 18.69, based on 391 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biohit Oyj's current Forward PE Ratio of 18.20 is 2.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Biohit Oyj and its competitors. For the Medical Devices & Instruments industry, the median Forward PE Ratio is 18.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biohit Oyj's current Forward PE Ratio is 18.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biohit Oyj stock overvalued right now?
Based on GuruFocus' analysis, Biohit Oyj (LTS:0DRP) is currently considered Fairly Valued. The stock's GF Value™ is €2.71, compared to a current price of €2.73 — trading 0.7% above its estimated fair value. The current Forward PE Ratio is 18.20 and 2.6% below the Medical Devices & Instruments industry median of 18.69. Biohit Oyj's overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Biohit Oyj (LTS:0DRP), the current Forward PE Ratio is 18.20 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biohit Oyj (LTS:0DRP) Overvalued in 2026?
Based on GuruFocus' analysis, Biohit Oyj stock appears to be overvalued.
The current stock price of €2.73 is trading 0.7% above its estimated GF Value™ of €2.71.
GuruFocus considers Biohit Oyj to be Fairly Valued.
Key valuation signals for LTS:0DRP:
Forward PE Ratio: 18.20
GF Value™: €2.71 vs. price of €2.73 (0.7% above fair value)
Industry Position: 2.6% below the Medical Devices & Instruments median (#176 of 391)
No single metric tells the full story. See the LTS:0DRP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biohit Oyj is a globally operating Finnish biotechnology company that develops diagnostic and other health products. Its products include GastroPanel quick test assesses the structure and function of the stomach lining; ColonView quick test is an immunochemical fecal occult blood test (FIT) developed; Acetium capsules protect the stomach lining from carcinogenic acetaldehyde, especially in people with acid-free stomachs. The company's product portfolio consists of diagnostic tests, analysis systems, products binding carcinogenic acetaldehyde into a harmless compound and monoclonal antibodies.
78GF Score
Get the complete analysis for LTS:0DRP
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0DRP has been successfully added to your 
